Protagonist Therapeutics, Inc. (PTGX)
| Market Cap | 6.44B |
| Revenue (ttm) | 46.02M |
| Net Income (ttm) | -130.15M |
| Shares Out | 63.81M |
| EPS (ttm) | -2.05 |
| PE Ratio | n/a |
| Forward PE | 33.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 432,455 |
| Open | 99.50 |
| Previous Close | 98.51 |
| Day's Range | 97.79 - 102.47 |
| 52-Week Range | 41.29 - 107.84 |
| Beta | 2.11 |
| Analysts | Strong Buy |
| Price Target | 108.23 (+7.29%) |
| Earnings Date | May 7, 2026 |
About PTGX
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class or... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price target is $108.23, which is an increase of 7.29% from the latest price.
News
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 millio...
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accor...
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results fur...
Protagonist Therapeutics Transcript: FDA announcement
ICOTYDE, the first oral IL-23 receptor blocker, received FDA approval for moderate-to-severe plaque psoriasis, supported by robust phase III data and a clean safety profile. The approval triggers significant milestone payments and positions the product to compete with and expand beyond injectable biologics.
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met...
Protagonist Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The discussion highlighted a robust pipeline of novel oral and injectable peptide therapeutics, with two lead assets nearing potential approval and a diversified R&D focus in immunology, hematology, and obesity. Strategic partnerships and financial strength support continued innovation and market expansion.
Protagonist Therapeutics Transcript: The Citizens Life Sciences Conference 2026
The company leverages deep expertise in peptide therapeutics, with two late-stage partnered assets expected to receive regulatory decisions in Q3. Strong partnerships, a robust pipeline in I&I and obesity, and a solid financial position enable continued innovation and multiple value inflection points in 2026.
Protagonist Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Two partnered products are expected to receive FDA approval in 2026, with significant milestone payments and surplus cash anticipated. The pipeline features first-in-class oral IL-23 and IL-17 assets, innovative obesity candidates, and a robust peptide platform, positioning for market disruption and shareholder value creation.
Protagonist Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted a robust pipeline with two near-term launches, strong clinical data for oral IL-23 in psoriasis and IBD, and significant market opportunities. Strategic partnerships, financial independence, and a focus on innovation and differentiation underpin future growth.
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Dr...
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.) NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential appro...
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for ...
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant growth is expected over the next two years with two near-term product launches, a robust pipeline of fully owned and partnered assets, and strong financials supporting both R&D and shareholder returns. Strategic focus includes expanding discovery, pharma partnerships for large markets, and operational scaling.
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Applica...
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from th...
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was s...
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the...
RTW Investments' Rod Wong: Expect more deals in biotech space
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto...
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.
Johnson & Johnson in Talks to Buy Protagonist Therapeutics
The two companies are already codeveloping a treatment for ulcerative colitis.
Protagonist Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Breakthrough designation was regained for rusfertide after strong phase 3 results in polycythemia vera, with NDA filing planned by year-end and a $1–2 billion market opportunity. Strategic opt-in/opt-out decisions could fund R&D and share buybacks. Pipeline assets show strong differentiation and clinical progress.
Protagonist Therapeutics Transcript: Citi's Biopharma Back to School Conference
The summit highlighted advances in peptide therapeutics, with rusfertide progressing toward NDA filing and a strategic partnership with Takeda. Icotrokinra's strong clinical profile and J&J partnership position it for significant market impact, while new obesity and IL-17 programs expand the pipeline.